Literature DB >> 31644894

Regulation of adipocyte differentiation and metabolism by lansoprazole.

Ameena Benchamana1, Hiroyuki Mori2, Ormond A MacDougald2, Sunhapas Soodvilai3.   

Abstract

AIMS: Lansoprazole (LPZ) is one of the most commonly prescribed drugs for treatment of acid-related diseases, and it is increasingly recognized for its potential application as an anti-diabetic therapy. Although LPZ target tissues remain poorly understood, possible sites of action include adipose tissue. In this study, we assessed effects of LPZ on adipocyte differentiation and function by using 3T3-L1 preadipocytes and HFD-induced obesity mice as an in vitro and in vivo model, respectively. MAIN
METHODS: Oil red O staining and intracellular triacylglycerol content were used to determine lipid accumulation. Glucose uptake was performed to measure mature adipocyte function. Expression of adipocyte genes was determined by qRT-PCR and immunoblotting. KEY
FINDINGS: LPZ has dual effects on differentiation of 3T3-L1 cells. At low concentrations, LPZ enhanced adipocyte differentiation via induction of PPARγ and C/EBPα, two master adipogenic transcription factors, as well as lipogenic proteins, ACC1 and FASN. Increasing of adipocyte number subsequently increased basal and insulin-stimulated glucose uptake, and expression of Glut4 mRNA. Conversely, high concentrations of LPZ strongly inhibited differentiation and expression of PPARγ and C/EBPα, and maintained expression of preadipocytes markers, β-catenin and Pref-1. Inhibition of adipogenesis by LPZ reduced mature adipocyte number, Glut4 mRNA expression and insulin-stimulated glucose uptake. In addition, treatment with LPZ at 200 mg/kg significantly reduced body weight gain and total fat mass in HFD-induced obese mice. SIGNIFICANCE: These results indicate that effects of LPZ on adipocyte differentiation are dependent on concentration and are correlated with PPARγ and C/EBPα.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adipogenesis; Anti-diabetic; Lansoprazole; Proton pump inhibitor

Mesh:

Substances:

Year:  2019        PMID: 31644894      PMCID: PMC7058925          DOI: 10.1016/j.lfs.2019.116897

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  31 in total

Review 1.  Drug repositioning: identifying and developing new uses for existing drugs.

Authors:  Ted T Ashburn; Karl B Thor
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients - a retrospective analysis.

Authors:  Karin D Hove; Kristine Færch; Thóra B Bödvarsdóttir; Allan E Karlsen; Jacob S Petersen; Allan Vaag
Journal:  Diabetes Res Clin Pract       Date:  2010-12       Impact factor: 5.602

3.  Central control of glucose homeostasis.

Authors:  Antonella Puglianiello; Stefano Cianfarani
Journal:  Rev Diabet Stud       Date:  2006-08-10

4.  Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice.

Authors:  W L Suarez-Pinzon; G S Cembrowski; A Rabinovitch
Journal:  Diabetologia       Date:  2009-05-20       Impact factor: 10.122

5.  Insulin signalling and the regulation of glucose and lipid metabolism.

Authors:  A R Saltiel; C R Kahn
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

6.  Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.

Authors:  Kohzo Takebayashi; Shintaro Sakurai; Tatsuhiko Suzuki; Kenichiro Hori; Tomoko Terasawa; Rika Naruse; Kenji Hara; Mariko Suetsugu; Takafumi Tsuchiya; Hiromi Aoki; Takashi Hamasaki; Hiroshi Shuutou; Toshihiko Inukai
Journal:  Endocr J       Date:  2014-09-02       Impact factor: 2.349

7.  Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin.

Authors:  Jiajian Liu; Hong Wang; Ying Zuo; Stephen R Farmer
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

8.  Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-associating protein 1.

Authors:  Tomohisa Takagi; Yuji Naito; Hitomi Okada; Takeshi Ishii; Katsura Mizushima; Satomi Akagiri; Satoko Adachi; Osamu Handa; Satoshi Kokura; Hiroshi Ichikawa; Ken Itoh; Masayuki Yamamoto; Hirofumi Matsui; Toshikazu Yoshikawa
Journal:  J Pharmacol Exp Ther       Date:  2009-07-23       Impact factor: 4.030

Review 9.  Transcriptional regulation of gene expression during adipocyte differentiation.

Authors:  O A MacDougald; M D Lane
Journal:  Annu Rev Biochem       Date:  1995       Impact factor: 23.643

10.  Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.

Authors:  Jai Moo Shin; Nayoung Kim
Journal:  J Neurogastroenterol Motil       Date:  2013-01-08       Impact factor: 4.924

View more
  5 in total

Review 1.  The emerging roles of PHOSPHO1 and its regulated phospholipid homeostasis in metabolic disorders.

Authors:  Yi Liu; Yingting Wu; Mengxi Jiang
Journal:  Front Physiol       Date:  2022-07-26       Impact factor: 4.755

2.  Ceiling culture of human mature white adipocytes with a browning agent: A novel approach to induce transdifferentiation into beige adipocytes.

Authors:  Yufei He; Zhuokai Liang; Jing Wang; Haojing Tang; Jian Li; Junrong Cai; Yunjun Liao
Journal:  Front Bioeng Biotechnol       Date:  2022-08-15

3.  Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats

Authors:  Burak Dik; Devran Coşkun; Emre Bahçivan; Kamil Üney
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973

4.  Molecular mechanism of benzo [a] pyrene regulating lipid metabolism via aryl hydrocarbon receptor.

Authors:  Wei Lou; Meng-di Zhang; Qi Chen; Tu-Ya Bai; Yu-Xia Hu; Feng Gao; Jun Li; Xiao-Li Lv; Qian Zhang; Fu-Hou Chang
Journal:  Lipids Health Dis       Date:  2022-01-20       Impact factor: 3.876

5.  Effects of SPARCL1 on the proliferation and differentiation of sheep preadipocytes.

Authors:  Cheng Xiao; Hai Guo Jin; Li Chun Zhang; Jian Qiang Liu; Ming He; Hui Hai Ma; Yong Sheng Yu; Yang Cao
Journal:  Adipocyte       Date:  2021-12       Impact factor: 4.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.